Core Viewpoint - On September 11, Oriental Bio held a performance briefing for the first half of 2025, highlighting its focus on expanding its animal health products, particularly vaccines and diagnostic reagents, in both domestic and European-American markets [1] Company Summary - The management indicated that the company is accelerating the registration of products in the domestic and European-American markets based on existing certified products [1]

Group 1 - The company announced the completion of a share buyback on September 11, 2025, having repurchased 1,801,328 shares [1] - The repurchased shares represent 0.8935% of the company's total share capital of 201,600,000 shares [1]

格隆汇9月11日丨东方生物(688298.SH)公布，2025年9月11日，公司完成回购，已实际回购公司股份 1,801,328股，占公司总股本201,600,000.00股的比例为0.8935%，回购最低价格26.45元/股，回购最高价 格29.52元/股，回购均价27.75元/股，使用资金总额4,999.4277万元（不含印花税、交易佣金等交易费 用）。 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-050 浙江东方基因生物制品股份有限公司 关于股份回购实施结果暨股份变动的公告 （四）本次回购使用的资金为公司自有资金及股票回购专项贷款资金，不会 对公司的经营、盈利能力和未来发展产生重大影响，不会导致公司控制权发生变 化，回购后公司的股权分布情况符合上市公司的条件，不会影响公司的上市地位。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/6/28 | | | | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 6 26 日~2025 年 月 25 | 年 | 月 | 9 日 | | 预计回购金额 | 2,500万元~5,000万元 | | | | | 回购价格上限 | 32.44元/股 | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | √为维护公司价值及股东权 ...

Group 1 - The company has completed a share buyback, repurchasing 1.8013 million shares, which accounts for 0.8935% of the total share capital [1] - The buyback price ranged from 26.45 yuan per share to 29.52 yuan per share, with a total expenditure of 49.9943 million yuan [1] - The repurchased shares will be used to maintain the company's value and protect shareholder interests, and will be sold through centralized bidding 12 months after the announcement of the buyback results [1]

Market Performance - The pharmaceutical sector experienced a decline of -1.91% on September 9, 2025, underperforming the CSI 300 index by 1.21 percentage points, ranking 28th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, pharmaceutical distribution (-0.52%), blood products (-0.62%), and in vitro diagnostics (-0.73%) performed relatively better, while medical R&D outsourcing (-3.63%), medical devices (-2.47%), and medical consumables (-2.06%) lagged behind [1] - Top three gainers included Rongchang Bio (+11.92%), Hehua Co. (+10.07%), and Zhend Medical (+10.00%), while the largest decliners were Yifang Bio (-11.74%), Huahai Pharmaceutical (-10.00%), and Chenxin Pharmaceutical (-8.42%) [1] Industry News - BMS announced positive results from the Phase II clinical trial of Pumitamig, a bispecific antibody developed in collaboration with BioNTech for the treatment of extensive-stage small cell lung cancer (ES-SCLC), showing a confirmed objective response rate (cORR) of 76.3% and a disease control rate (DCR) of 100% [2] - Pumitamig targets PD-L1 and VEGF-A, designed to restore the function of effector T cells in the tumor microenvironment while locally neutralizing the effects of VEGF-A [2] Company News - Heng Rui Medicine (600276) announced that its subsidiary Chengdu Shengdi Pharmaceutical received approval from the National Medical Products Administration for its product, Eicosapentaenoic Acid Ethyl Ester Soft Capsules, to lower triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/dL) [3] - Taiji Group (600129) reported that its subsidiary Fuling Pharmaceutical Factory received a clinical trial approval notice for Semaglutide injection for the treatment of type 2 diabetes [3] - Huahai Pharmaceutical (600521) disclosed that its subsidiary Huahai Jiancheng underwent a pre-approval inspection by the FDA from July 14 to 18, 2025, covering the overall quality management system and the active pharmaceutical ingredient Gabapentin, which met the CGMP requirements [3] - Dongfang Bio (688298) announced that its subsidiary Laihe Bio obtained a Class III medical device registration certificate for its influenza virus antigen detection kit (colloidal gold method), enhancing the company's product portfolio in the respiratory joint detection field [3]

证券代码：688298 证券简称：东方生物 公告编号：2025-048 浙江东方基因生物制品股份有限公司 关于独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"公司"）董事会于近日收到 独立董事李波先生的书面辞职报告，因个人工作原因，辞去其担任的公司独立董事 及董事会提名委员会委员、战略与投资委员会委员、薪酬与考核委员会委员职务。 根据《公司法》《公司章程》等有关规定，李波先生辞去上述职务自其辞职报 告送达公司董事会时生效。李波先生的辞职不会导致公司董事会低于法定最低人数， 不会导致独立董事人数少于董事会成员的三分之一，不会影响公司董事会和董事会 各专门委员会的正常运作。 公司将按照有关规定，尽快完成独立董事以及董事会专门委员会委员的补选工 作，确保董事会及各专门委员会的构成符合法律法规的规定。 李波先生在担任公司独立董事及董事会各专门委员会委员职务期间，始终秉持 独立、客观、审慎的原则，勤勉尽责地履行职责，为公司规范运作做出了重要贡献， 公司董事会对李波先生的 ...

证券代码：688298 证券简称：东方生物 公告编号：2025-049 三、境外合作取得医疗器械注册证基本情况如下： 浙江东方基因生物制品股份有限公司 关于自愿披露获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 全资子公司Healgen Scientific LLC（以下简称"美国衡健"）、控股子公司杭 州莱和生物技术有限公司（以下简称"莱和生物"）近日取得以下几款医疗器械 产品的注册证书，内容公告如下： 一、境内医疗器械注册证基本情况如下： | 产品名称 | 证书编号 | 适用国家 及证书类 | 预期用途 | 有效期 | 持证 公司 | | --- | --- | --- | --- | --- | --- | | | | 型 | | | | | 甲型/乙型流感病毒抗原 检测试剂盒（胶体金法） | 国械注准 | 三类 | 本产品用于体外定性鉴别检测人鼻 拭子、咽拭子样本中的甲型/乙型流 | 2025/8/14 - | 莱和 | ...

Core Viewpoint - Dongfang Biological (688298.SH) announced that its wholly-owned subsidiary Healgen Scientific LLC and its holding subsidiary Hangzhou Laihe Biotechnology Co., Ltd. have obtained registration certificates for multiple medical device products, enhancing their product offerings in various markets [1] Group 1: Product Registration and Market Expansion - The respiratory combined detection reagents have received certification in China, the EU, and Israel, enriching the company's product layout in these regions and expanding the variety of products available for sale, which is beneficial for addressing seasonal respiratory infection detection [1] - The fully automated biochemical analyzer and its series of lyophilized biochemical reagents have been certified in Peru, broadening the company's product offerings in the South American market, aiding in the detection of liver and pancreatic systems, urinary systems, cardiovascular diseases, as well as metabolic disorders related to glucose, lipids, and water-salt [1]

Core Viewpoint - Dongfang Biological (688298.SH) announced that its wholly-owned subsidiary Healgen Scientific LLC and its controlling subsidiary Hangzhou Laihe Biotechnology Co., Ltd. have recently obtained registration certificates for multiple medical device products [1] Group 1: Product Registration and Market Expansion - The company's respiratory joint detection reagents have received certification in China, the EU, and Israel, enhancing its product offerings in these regions and expanding the range of products available for sale [1] - The full-automatic biochemical analyzer and its series of lyophilized biochemical reagents have been certified in Peru, broadening the company's product offerings in the South American market [1] Group 2: Applications and Benefits - The respiratory joint detection products are beneficial for addressing routine seasonal respiratory infection disease testing [1] - The biochemical analyzer and reagents are intended for auxiliary detection of liver and pancreatic systems, urinary systems, cardiovascular diseases, as well as metabolic disorders related to glucose, lipids, and water-salt [1]